Summary

The global Protein Expression market is projected to reach USD 4.82 billion in 2029 and is from USD 3.41 billion by 2024, at a CAGR of 7.1% during the forecast period. Factors such as the increasing demand for biologics supported by the rise in R&D activities in the pharmaceutical and biopharmaceutical industry and the growing use of artificial intelligence and machine learning to enhance protein-based studies are supporting the growth of the market. Moreover, factors such as the ongoing shift toward the development of personalized medicines, the rise in outsourcing services for clinical activities, the growing emphasis on the use of plant-based and cell-free expression systems, and the development of synthetic protein production technologies provide growth opportunities for players within the protein expression market. However, the high cost of protein expression reagents and instruments and the challenges associated with various expression systems are expected to restrain the growth of this market.
“The product segment registered the highest growth rate in the protein expression market, by offerings, during the forecast period”
In 2023, the products segment registered the highest growth rate within the protein expression market by offerings. Factors such as the rise in protein-based research and increasing approvals and commercialization of biologics, such as antibodies and vaccines are supporting the high growth of this segment. The products segment includes various reagents & kits, expression vectors, competent cells, and instruments that aid during various phases of protein expression. Reagents & kits accounted for the largest segment of the protein expression products market due to the continuous demand for these products during the protein expression workflow. Advancements in protein expression technologies and the launch of new and efficient reagents and kits are also supporting the growth of this product segment. Additionally, the rising focus on personalized medicine and biologics, such as antibodies and vaccines, is creating more demand for these products.
“The academic research institutes registered the highest growth rate in the protein expression services market, by end user, during the forecast period”
The academic research institute end user segment registered the highest growth rate within the protein expression services market by end user during the forecast period. Factors such as the increasing demand for innovative research solutions for biological and biomedical research supported by an increase in funding and grants from governments and pharmaceutical companies are supporting the high growth of this end user segment. Moreover, there is an increase in the number of collaborations between research institutes and pharmaceutical companies for the development of protein-based therapies such as antibodies and vaccines for the treatment of various chronic illnesses. This high growth is projected to continue during the forecast period.
“North America: The largest and fastest-growing region in the Protein Expression market”
The protein expression market in North America is projected to register the highest growth rate during the forecast period. This high growth is attributed to the presence of an established biotechnology and pharmaceuticals sector focusing on the development of protein-based therapies leading to a high demand for protein expression products and services. The region has key protein expression products and services suppliers and end-users as well as advanced research facilities and large R&D expenditures. In addition, the rise of chronic conditions such as cancer and diabetes has also supported the need for new protein-based drugs, increasing the demand for efficient protein expression technologies. In addition, the support and funding from the government for life sciences research also support the large market share of North America in the global protein expression market.

The primary interviews conducted for this report can be categorized as follows:
• By Company Type: Tier 1 – 32%, Tier 2 – 44%, and Tier 3 – 24%
• By Designation: (Managers) - 45%, (CXOs, Directors)- 30%, and(Executives) - 25%
• By Region: North America -40%, Europe -25%, Asia-Pacific -20%, Latin America -5%, Middle East- 5%, Africa-5%
List of Companies Profiled in the Report:
• Thermo Fisher Scientific, Inc. (US)
• Merck KGaA (Germany)
• GenScript (US)
• Agilent Technologies, Inc. (US)
• Takara Bio Inc. (Japan)
• Lonza (Switzerland)
• Promega Corporation (US)
• OriGene Technologies, Inc. (US)
• Qiagen (Netherlands)
• Bio-Rad Laboratories, Inc. (US)
• Danaher Corporation (US)
• Sartorius AG (Germany)
• FUJIFILM Irvine Scientific, Inc. (Japan)
• Bioneer Corporation (South Korea)
• LGC Limited (UK)
• Sino Biological, Inc. (China)
• New England BioLabs (US)
• LifeSensors Inc. (US)
• Jena Bioscience GmbH (Germany)
• Charles River Laboratories (US)
• Corning Incorporated (US)
• Eurofins Scientific (Luxembourg)
• Ajinomoto Co., Inc. (Ajinomoto Bio-Pharma Services) (Japan)
• Syngene International Limited (India)
• Aragen Life Sciences Ltd. (India)
Research Coverage:
This report provides a detailed picture of the global Protein Expression Market. It aims at estimating the size and future growth potential of the market across different segments such as the system type, offerings, workflow, application, products end user, services end user, and region. The scope of the report covers detailed information regarding the major factors, such as drivers, restraints, challenges, and opportunities, influencing the growth of the protein expression market. A detailed analysis of the key industry players has been done to provide insights into their business overview, solutions, and services; key strategies; Contracts, partnerships, agreements, new product & service launches, mergers and acquisitions, and recent developments associated with the protein expression market. Competitive analysis of upcoming startups in the protein expression market ecosystem is covered in this report.
Reasons to buy this report :
The report will help the market leaders/new entrants in this market with information on the closest approximations of the revenue numbers for the overall protein expression market and the subsegments. This report will help stakeholders understand the competitive landscape and gain more insights to position their businesses better and plan suitable go-to-market strategies. The report also helps stakeholders understand the pulse of the market and provides them with information on key market drivers, restraints, challenges, and opportunities.
The report provides insights on the following pointers:
• Analysis of key drivers (Increasing demand for biologics, Rise in R&D in pharmaceutical and biopharmaceutical industries, Growing use of artificial intelligence and machine learning, Increasing shift toward personalized medicines, and Growing outsourcing of clinical activities), restraints (High cost of protein expression offerings and the dominance of small molecules in drug development), opportunities (Growing emphasis on plant-based and cell-free expression systems, Booming markets in emerging economies, Increasing development of new synthetic protein production technologies, and Growing use of recombinant proteins), and challenges (Production cost and efficiency issues) influencing the growth of the protein expression market.
• Product Development/Innovation: Detailed insights on upcoming technologies, research & development activities, and new product & service launches in the protein expression market
• Market Development: Comprehensive information about lucrative markets – the report analyses the protein expression market across varied regions.
• Market Diversification: Exhaustive information about new products & services, untapped geographies, recent developments, and investments in the protein expression market
• Competitive Assessment: In-depth assessment of market shares, growth strategies, and service offerings of leading players like Thermo Fisher Scientific Inc. (US), Merck KGaA (Germany), Danaher Corporation (US), Agilent Technologies, Inc. (US), Sartorius AG (Germany), GenScript (US), Takara Bio Inc. (Japan), Lonza (Switzerland), among others in protein expression market.

ページTOPに戻る

Table of Contents

1 INTRODUCTION 44
1.1 STUDY OBJECTIVES 44
1.2 MARKET DEFINITION 44
1.3 STUDY SCOPE 45
1.3.1 MARKETS COVERED AND REGIONAL SCOPE 45
1.3.2 INCLUSIONS AND EXCLUSIONS 46
1.3.3 YEARS CONSIDERED 47
1.4 CURRENCY CONSIDERED 47
1.5 STAKEHOLDERS 47
1.6 SUMMARY OF CHANGES 48
2 RESEARCH METHODOLOGY 49
2.1 RESEARCH DATA 49
2.1.1 SECONDARY DATA 50
2.1.2 PRIMARY DATA 50
2.2 MARKET ESTIMATION METHODOLOGY 52
2.2.1 MARKET ESTIMATION 52
2.2.2 INSIGHTS FROM PRIMARY EXPERTS 54
2.2.3 TOP-DOWN APPROACH 55
2.3 MARKET GROWTH RATE PROJECTIONS 56
2.4 MARKET BREAKDOWN AND DATA TRIANGULATION 58
2.5 RESEARCH ASSUMPTIONS 59
2.6 RESEARCH LIMITATIONS 59
2.7 RISK ANALYSIS 60
3 EXECUTIVE SUMMARY 61
4 PREMIUM INSIGHTS 66
4.1 PROTEIN EXPRESSION MARKET OVERVIEW 66
4.2 NORTH AMERICA: PROTEIN EXPRESSION MARKET, BY OFFERING AND COUNTRY, 2023 67
4.3 PROTEIN EXPRESSION MARKET SHARE, BY SYSTEM TYPE, 2024 VS. 2029 67
4.4 PROTEIN EXPRESSION PRODUCTS MARKET, BY END USER, 2023 68
4.5 PROTEIN EXPRESSION SERVICES MARKET, BY END USER, 2023 68
4.6 PROTEIN EXPRESSION MARKET, BY COUNTRY 69
 
5 MARKET OVERVIEW 70
5.1 INTRODUCTION 70
5.2 MARKET DYNAMICS 70
5.2.1 DRIVERS 71
5.2.1.1 Increasing demand for biologics 71
5.2.1.2 Rise in R&D in pharmaceutical and biopharmaceutical industries 74
5.2.1.3 Growing use of artificial intelligence and machine learning 74
5.2.1.4 Increasing shift toward personalized medicines 75
5.2.1.5 Growing outsourcing of clinical activities 76
5.2.2 RESTRAINTS 77
5.2.2.1 High cost of protein expression offerings 77
5.2.2.2 Renewed focus on small molecules in drug development 77
5.2.3 OPPORTUNITIES 78
5.2.3.1 Growing emphasis on plant-based and cell-free expression systems 78
5.2.3.2 Booming market in emerging economies 78
5.2.3.3 Increasing development of synthetic protein production technologies 79
5.2.3.4 Growing use of recombinant proteins 80
5.2.4 CHALLENGES 80
5.2.4.1 Production cost and efficiency issues 80
5.3 TRENDS/DISRUPTIONS IMPACTING CUSTOMER BUSINESS 81
5.4 PRICING ANALYSIS 82
5.4.1 AVERAGE SELLING PRICE TREND OF PROTEIN EXPRESSION PRODUCTS 82
5.4.2 AVERAGE SELLING PRICE, BY KEY PLAYER 83
5.4.2.1 Average selling price of system types, by key player 83
5.4.2.2 Average selling price trend of protein expression instruments,
by key player 85
5.4.3 AVERAGE SELLING PRICE, BY REGION 86
5.4.3.1 Average selling price of protein expression consumable products,
by region 86
5.4.3.2 Average selling price trend of protein expression instruments,
by region 88
5.5 SUPPLY CHAIN ANALYSIS 89
5.6 VALUE CHAIN ANALYSIS 90
5.7 ECOSYSTEM ANALYSIS 93
5.8 INVESTMENT/FUNDING ACTIVITY 95
5.9 TECHNOLOGY ANALYSIS 96
5.9.1 KEY TECHNOLOGIES 96
5.9.1.1 Recombinant DNA technology 96
5.9.1.2 Transfection technologies 96
5.9.1.2.1 Reagent-based transfection 96
5.9.1.2.2 Instrument-based transfection 97
5.9.1.2.3 Virus-based transfection 98
5.9.1.3 Protein expression systems 98
5.9.1.3.1 Bacterial expression systems 99
5.9.1.3.2 Mammalian expression systems 99
5.9.1.3.3 Yeast expression systems 99
5.9.1.3.4 Insect expression systems 99
5.9.1.3.5 Cell-free expression systems 99
5.9.2 ADJACENT TECHNOLOGIES 100
5.9.2.1 Extraction technologies 100
5.9.2.1.1 Non-mechanical methods 100
5.9.2.1.2 Mechanical methods 101
5.9.2.2 Purification and characterization technologies 101
5.9.2.2.1 Protein purification technologies 101
5.9.2.2.2 Protein characterization technologies 101
5.9.3 COMPLEMENTARY TECHNOLOGIES 102
5.9.3.1 High-throughput technologies 102
5.9.3.2 Computation protein designing 102
5.10 PATENT ANALYSIS 103
5.11 TRADE ANALYSIS 106
5.11.1 IMPORT DATA 106
5.11.2 EXPORT DATA 108
5.12 KEY CONFERENCES AND EVENTS, 2024–2025 109
5.13 REGULATORY ANALYSIS 110
5.13.1 REGULATORY LANDSCAPE 110
5.13.1.1 North America 110
5.13.1.2 Europe 110
5.13.1.3 Emerging economies 111
5.13.2 REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS 111
5.14 PORTER’S FIVE FORCES ANALYSIS 115
5.14.1 INTENSITY OF COMPETITIVE RIVALRY 116
5.14.2 BARGAINING POWER OF SUPPLIERS 116
5.14.3 BARGAINING POWER OF BUYERS 116
5.14.4 THREAT OF NEW ENTRANTS 116
5.14.5 THREAT OF SUBSTITUTES 117
5.15 KEY STAKEHOLDERS AND BUYING CRITERIA 117
5.15.1 KEY STAKEHOLDERS IN BUYING PROCESS 117
5.15.2 BUYING CRITERIA 118
5.15.2.1 Buying criteria for protein expression products 118
5.15.2.2 Buying criteria for protein expression services 120
 
5.16 IMPACT OF AI/GEN AI ON PROTEIN EXPRESSION MARKET 121
5.16.1 INTRODUCTION 121
5.16.2 MARKET POTENTIAL FOR PROTEIN EXPRESSION APPLICATIONS 121
5.16.3 AI USE CASES 122
5.16.4 KEY COMPANIES IMPLEMENTING AI 123
5.16.5 FUTURE OF GENERATIVE AI IN PROTEIN EXPRESSION ECOSYSTEM 123
6 PROTEIN EXPRESSION MARKET, BY OFFERING 124
6.1 INTRODUCTION 125
6.2 PRODUCTS 125
6.2.1 REAGENTS & KITS 128
6.2.1.1 Increasing use for cloning, transfection, purification, and characterization to spur growth 128
6.2.2 EXPRESSION VECTORS 131
6.2.2.1 Growing production of complex proteins to propel market 131
6.2.3 COMPETENT CELLS 133
6.2.3.1 Increasing demand for therapeutic proteins to expedite growth 133
6.2.4 INSTRUMENTS & SOFTWARE 136
6.2.4.1 Increasing demand for biopharmaceuticals and personalized therapies to augment growth 136
6.3 SERVICES 138
6.3.1 GROWING UTILIZATION OF PROTEIN EXPRESSION SERVICES FOR LARGE-SCALE PRODUCTION TO FUEL MARKET 138
7 PROTEIN EXPRESSION MARKET, BY SYSTEM TYPE 141
7.1 INTRODUCTION 142
7.2 MAMMALIAN CELL EXPRESSION SYSTEMS 142
7.2.1 CHINESE HAMSTER OVARY (CHO) CELL SYSTEMS 146
7.2.1.1 High viability, rapid growth, and improved expression levels to support growth 146
7.2.2 HUMAN EMBRYONIC KIDNEY (HEK 293) CELL SYSTEMS 148
7.2.2.1 Wide usage in transient transfection studies to augment growth 148
7.2.3 OTHER MAMMALIAN CELL SYSTEMS 151
7.3 PROKARYOTIC EXPRESSION SYSTEMS 154
7.3.1 ESCHERICHIA COLI SYSTEMS 157
7.3.1.1 High cell density and low cost of media to stimulate growth 157
7.3.2 OTHER PROKARYOTIC EXPRESSION SYSTEMS 159
7.4 INSECT CELL EXPRESSION SYSTEMS 162
7.4.1 BACULOVIRUS SYSTEMS 165
7.4.1.1 Increasing production of biologically active and functional recombinant proteins to speed up growth 165
7.4.2 OTHER INSECT CELL EXPRESSION SYSTEMS 167
 
7.5 YEAST EXPRESSION SYSTEMS 170
7.5.1 PICHIA SYSTEMS 173
7.5.1.1 Rising production of antibody fragments, and vaccines to fuel growth 173
7.5.2 SACCHAROMYCES SYSTEMS 175
7.5.2.1 Increasing use of saccharomyces systems for producing heterologous proteins to accelerate growth 175
7.5.3 OTHER YEAST EXPRESSION SYSTEMS 178
7.6 CELL-FREE EXPRESSION SYSTEMS 180
7.6.1 INCREASING DEMAND FOR RECOMBINANT PROTEINS TO SUPPORT MARKET 180
7.7 ALGAL-BASED EXPRESSION SYSTEMS 183
7.7.1 GROWING USE OF ALGAL-BASED EXPRESSION SYSTEMS IN ANTIBODY AND VACCINE GENERATION TO BOOST MARKET 183
8 PROTEIN EXPRESSION MARKET, BY WORKFLOW 186
8.1 INTRODUCTION 187
8.2 CLONING & TRANSFECTION 187
8.2.1 CONTINUOUS REPLENISHMENT OF CONSUMABLES AND REAGENTS TO SUPPORT MARKET 187
8.3 TRANSCRIPTION, TRANSLATION, AND POST-TRANSLATIONAL MODIFICATION (PTM) 190
8.3.1 GROWING NEED FOR FUNCTIONAL AND STABLE PROTEINS TO DRIVE MARKET 190
8.4 EXTRACTION, PURIFICATION, AND CHARACTERIZATION 192
8.4.1 NEED TO ADHERE TO REQUIRED STANDARDS FOR SUITABLE APPLICATIONS TO DRIVE MARKET 192
9 PROTEIN EXPRESSION MARKET, BY APPLICATION 195
9.1 INTRODUCTION 196
9.2 THERAPEUTIC APPLICATIONS 196
9.2.1 RISING DEMAND FOR BIOLOGICS THERAPIES TO FACILITATE GROWTH 196
9.3 RESEARCH APPLICATIONS 199
9.3.1 GROWING INTEREST IN PROTEOMICS, GENOMICS, AND DRUG DISCOVERY TO BOOST MARKET 199
9.4 INDUSTRIAL APPLICATIONS 202
9.4.1 INCREASING USE OF PROTEINS IN COSMETICS, TEXTILES, AND INDUSTRIAL ENZYMES TO PROMOTE GROWTH 202
10 PROTEIN EXPRESSION PRODUCTS MARKET, BY END USER 206
10.1 INTRODUCTION 207
10.2 PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES 207
10.2.1 INCREASING APPROVALS FOR BIOLOGICS TO STIMULATE GROWTH 207
10.3 ACADEMIC & RESEARCH INSTITUTES 210
10.3.1 RISE IN GOVERNMENT AND PRIVATE FUNDING TO CONTRIBUTE TO MARKET GROWTH 210
 
10.4 CONTRACT RESEARCH ORGANIZATIONS & CONTRACT DEVELOPMENT AND MANUFACTURING ORGANIZATIONS (CROS & CDMOS) 213
10.4.1 INCREASING OUTSOURCING AND COLLABORATIONS FOR PHARMACEUTICAL MANUFACTURING AND CLINICAL TRIALS TO SUSTAIN MARKET 213
10.5 OTHER END USERS 217
11 PROTEIN EXPRESSION SERVICES MARKET, BY END USER 220
11.1 INTRODUCTION 221
11.2 PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES 221
11.2.1 INCREASING SHIFT TOWARD DRUG DEVELOPMENT OUTSOURCING TO FAVOR GROWTH 221
11.3 ACADEMIC & RESEARCH INSTITUTES 224
11.3.1 RISING PARTNERSHIPS BETWEEN ACADEMIA AND CONTRACT RESEARCH ORGANIZATIONS TO AID GROWTH 224
11.4 OTHER END USERS 227
12 PROTEIN EXPRESSION MARKET, BY REGION 230
12.1 INTRODUCTION 231
12.2 NORTH AMERICA 231
12.2.1 MACROECONOMIC OUTLOOK FOR NORTH AMERICA 237
12.2.2 US 237
12.2.2.1 Growing focus on developing new therapeutics and protein-based drugs to drive market 237
12.2.3 CANADA 242
12.2.3.1 Increasing incidence of cancer and prevalence of public-private partnerships to sustain growth 242
12.3 EUROPE 246
12.3.1 MACROECONOMIC OUTLOOK FOR EUROPE 251
12.3.2 GERMANY 252
12.3.2.1 Increasing proteomics-based research and healthcare investments to promote growth 252
12.3.3 UK 256
12.3.3.1 Growing development of immunotherapies, vaccines, and proteomics to fuel market 256
12.3.4 FRANCE 260
12.3.4.1 Rise in funding for proteomics and genomics to spur growth 260
12.3.5 ITALY 265
12.3.5.1 Growing life science research supported by universities and research institutions to boost market 265
12.3.6 SPAIN 269
12.3.6.1 Increasing international collaborations for drug development to fuel market 269
 
12.3.7 NETHERLANDS 273
12.3.7.1 Presence of advanced infrastructure to fuel market 273
12.3.8 REST OF EUROPE 277
12.4 ASIA PACIFIC 281
12.4.1 MACROECONOMIC OUTLOOK FOR ASIA PACIFIC 287
12.4.2 CHINA 288
12.4.2.1 Extensive government funding in genomics and protein research to boost market 288
12.4.3 JAPAN 292
12.4.3.1 Increasing initiatives by government associations in life sciences sector to support market growth 292
12.4.4 INDIA 297
12.4.4.1 Rising collaborations between private sector and academia to facilitate growth 297
12.4.5 AUSTRALIA 301
12.4.5.1 Growing focus on developing new proteins and peptides to drive market 301
12.4.6 SOUTH KOREA 305
12.4.6.1 Increasing research & development of novel therapies to facilitate growth 305
12.4.7 REST OF ASIA PACIFIC 310
12.5 LATIN AMERICA 314
12.5.1 MACROECONOMIC OUTLOOK FOR LATIN AMERICA 319
12.5.2 BRAZIL 320
12.5.2.1 Growing industrial investments to propel market 320
12.5.3 MEXICO 324
12.5.3.1 Increase in chronic diseases and robust research ecosystem to expedite growth 324
12.5.4 ARGENTINA 328
12.5.4.1 Rise in biotechnology and pharmaceutical research & development to augment growth 328
12.5.5 REST OF LATIN AMERICA 332
12.6 MIDDLE EAST 336
12.6.1 MACROECONOMIC OUTLOOK FOR MIDDLE EAST 341
12.6.2 GCC COUNTRIES 342
12.6.2.1 Strategic investments between government authorities and private players to drive market 342
12.6.3 REST OF MIDDLE EAST 346
12.7 AFRICA 350
12.7.1 FAVORABLE INSURANCE PROGRAMS AND CLINICAL TRIALS TO CONTRIBUTE TO MARKET GROWTH 350
12.7.2 MACROECONOMIC OUTLOOK FOR AFRICA 354
 
13 COMPETITIVE LANDSCAPE 356
13.1 OVERVIEW 356
13.2 KEY PLAYER STRATEGY/RIGHT TO WIN, 2021–2024 356
13.3 REVENUE ANALYSIS, 2021–2023 359
13.4 MARKET SHARE ANALYSIS, 2023 360
13.5 COMPANY EVALUATION QUADRANT: KEY PLAYERS, 2023 363
13.5.1 STARS 363
13.5.2 EMERGING LEADERS 363
13.5.3 PERVASIVE PLAYERS 363
13.5.4 PARTICIPANTS 364
13.5.5 COMPANY FOOTPRINT: KEY PLAYERS, 2023 365
13.5.5.1 Company footprint 365
13.5.5.2 Region footprint 366
13.5.5.3 Offering footprint 367
13.5.5.4 Expression system footprint 369
13.5.5.5 Application footprint 371
13.6 COMPANY EVALUATION MATRIX: STARTUPS/SMES, 2023 372
13.6.1 PROGRESSIVE COMPANIES 372
13.6.2 RESPONSIVE COMPANIES 372
13.6.3 DYNAMIC COMPANIES 372
13.6.4 STARTING BLOCKS 372
13.6.5 COMPETITIVE BENCHMARKING: STARTUPS/SMES, 2023 374
13.6.5.1 Detailed list of key startups/SMES 374
13.6.5.2 Competitive benchmarking of startups/SMEs 375
13.7 COMPANY VALUATION AND FINANCIAL METRICS 376
13.7.1 COMPANY VALUATION 376
13.7.2 FINANCIAL METRICS 376
13.8 BRAND/PRODUCT COMPARISON 377
13.9 COMPETITIVE SCENARIO 378
13.9.1 PRODUCT/SERVICE LAUNCHES 378
13.9.2 DEALS 379
13.9.3 EXPANSIONS 380
 
14 COMPANY PROFILES 382
14.1 KEY PLAYERS 382
14.1.1 THERMO FISHER SCIENTIFIC INC. 382
14.1.1.1 Business overview 382
14.1.1.2 Products and services offered 383
14.1.1.3 Recent developments 388
14.1.1.3.1 Product/Service launches 388
14.1.1.3.2 Deals 389
14.1.1.3.3 Expansions 389
14.1.1.4 MnM view 390
14.1.1.4.1 Key strengths 390
14.1.1.4.2 Strategic choices 390
14.1.1.4.3 Weaknesses and competitive threats 391
14.1.2 MERCK KGAA 392
14.1.2.1 Business overview 392
14.1.2.2 Products and services offered 393
14.1.2.3 Recent developments 395
14.1.2.3.1 Deals 395
14.1.2.3.2 Expansions 396
14.1.2.4 MnM view 398
14.1.2.4.1 Key strengths 398
14.1.2.4.2 Strategic choices 398
14.1.2.4.3 Weaknesses and competitive threats 398
14.1.3 DANAHER CORPORATION 399
14.1.3.1 Business overview 399
14.1.3.2 Products and services offered 400
14.1.3.3 Recent developments 402
14.1.3.3.1 Product/Service launches 402
14.1.3.3.2 Deals 403
14.1.3.3.3 Expansions 403
14.1.3.4 MnM view 404
14.1.3.4.1 Key strengths 404
14.1.3.4.2 Strategic choices 404
14.1.3.4.3 Weaknesses and competitive threats 404
14.1.4 AGILENT TECHNOLOGIES, INC. 405
14.1.4.1 Business overview 405
14.1.4.2 Products and services offered 406
14.1.4.3 MnM view 409
14.1.4.3.1 Key strengths 409
14.1.4.3.2 Strategic choices 409
14.1.4.3.3 Weaknesses and competitive threats 409
 
14.1.5 SARTORIUS AG 410
14.1.5.1 Business overview 410
14.1.5.2 Products and services offered 411
14.1.5.3 Recent developments 412
14.1.5.3.1 Deals 412
14.1.5.3.2 Expansions 413
14.1.5.4 MnM view 414
14.1.5.4.1 Key strength 414
14.1.5.4.2 Strategic choices 414
14.1.5.4.3 Weaknesses and competitive threats 414
14.1.6 GENSCRIPT 415
14.1.6.1 Business overview 415
14.1.6.2 Products and services offered 416
14.1.6.3 Recent developments 417
14.1.6.3.1 Product/Service launches 417
14.1.6.4 MnM view 418
14.1.6.4.1 Key strengths 418
14.1.6.4.2 Strategic choices 418
14.1.6.4.3 Weaknesses and competitive threats 418
14.1.7 TAKARA BIO INC. 419
14.1.7.1 Business overview 419
14.1.7.2 Products and services offered 421
14.1.8 BIO-RAD LABORATORIES, INC. 423
14.1.8.1 Business overview 423
14.1.8.2 Products and services offered 424
14.1.9 QIAGEN 426
14.1.9.1 Business overview 426
14.1.9.2 Products and services offered 428
14.1.10 CHARLES RIVER LABORATORIES 429
14.1.10.1 Business overview 429
14.1.10.2 Products and services offered 431
14.1.11 CORNING INCORPORATED 432
14.1.11.1 Business overview 432
14.1.11.2 Products and services offered 433
14.1.12 LONZA 435
14.1.12.1 Business overview 435
14.1.12.2 Products and services offered 436
14.1.12.3 Recent developments 438
14.1.12.3.1 Product/Service launches 438
14.1.12.3.2 Deals 438
 
14.1.13 FUJIFILM IRVINE SCIENTIFIC, INC. 439
14.1.13.1 Business overview 439
14.1.13.2 Products and services offered 440
14.1.13.3 Recent developments 442
14.1.13.3.1 Product/Service launches 442
14.1.13.3.2 Deals 442
14.1.13.3.3 Expansions 443
14.1.14 SYNGENE INTERNATIONAL LIMITED 444
14.1.14.1 Business overview 444
14.1.14.2 Products and services offered 445
14.1.14.3 Recent developments 445
14.1.14.3.1 Product/Service launches 445
14.1.15 LGC LIMITED 446
14.1.15.1 Business overview 446
14.1.15.2 Products and services offered 447
14.1.16 EUROFINS SCIENTIFIC 448
14.1.16.1 Business overview 448
14.1.16.2 Products and services offered 449
14.1.17 AJINOMOTO CO., INC. 450
14.1.17.1 Business overview 450
14.1.17.2 Products and services offered 451
14.2 OTHER PLAYERS 452
14.2.1 PROMEGA CORPORATION 452
14.2.2 SINO BIOLOGICAL, INC. 453
14.2.3 RAYBIOTECH, INC. 454
14.2.4 BIONEER CORPORATION 455
14.2.5 ORIGENE TECHNOLOGIES, INC. 456
14.2.6 NEW ENGLAND BIOLABS 457
14.2.7 ACCURUS BIOSCIENCES 458
14.2.8 ARAGEN LIFE SCIENCES LTD. 459
14.2.9 OXFORD EXPRESSION TECHNOLOGIES LTD 460
14.2.10 PROTEOGENIX INC. 461
14.2.11 ABEOMICS 462
15 APPENDIX 463
15.1 DISCUSSION GUIDE 463
15.2 KNOWLEDGESTORE: MARKETSANDMARKETS’ SUBSCRIPTION PORTAL 467
15.3 CUSTOMIZATION OPTIONS 469
15.4 RELATED REPORTS 469
15.5 AUTHOR DETAILS 470